comment: >
  
  Yeah, each of these drugs is a step to developing new treatments by revealing information that may not have been previously visible.
context: Lecanemab, a monoclonal antibody, is not a cure but works by binding to amyloid beta, a hallmark of Alzheimer’s disease. In late November, results from an 18-month Phase 3 clinical trial published in The New England Journal of Medicine showed that lecanemab “reduced markers of amyloid in early Alzheimer’s disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events.”
  
  seems to be treating down stream effects of Alzheimer’s and isn’t yet close enough to treating the early mechanisms of the disease, but if it buys some time and becomes one of many new tools in our belt where previously there were none, huzzah!